The Myth of Statin-Induced Hepatotoxicity

Bader, Ted

doi:10.1038/ajg.2010.102

Cited by 71 publications

(64 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As mentioned above, controlled observations support a significant reduction in portal hypertension with statins [10], and antiviral effects of these medications have been increasingly reported [3,14].…”

Section: Biopsy-proven Versus Clinically Diagnosed Cirrhosismentioning

confidence: 81%

“…Although the hepatotoxicity observed in animals during statin development led to the requirement for liver enzyme monitoring in patients, numerous studies published in the past several years have emphasized the safety of statins in patients with underlying CLD [1][2][3][4]6]. Furthermore, statins prevent HCC among other malignancies [11][12][13].…”

Section: How To Monitor Laes In Patients With Cirrhosis Taking a Statin?mentioning

confidence: 99%

“…While it would be easy to call for additional studies to confirm the findings of reduced mortality in cirrhotics receiving a statin before considering their routine use in this setting, the time and effort required to perform such long-term follow-up studies would be substantial. With the current literature supporting safe use in CLD [1][2][3][4]6] as well as substantial clinical benefits [6,[8][9][10][11][12][13][14] with no serious adverse consequences, we already have sufficient evidence to recommend statins in our patients with cirrhosis at this time. As the saying goes, ''The difficult we do immediately.…”

Section: Should Statins Be Routinely Prescribed To Patients With Cirrmentioning

confidence: 99%

“…Over the past decade, however, data have consistently supported the safety of statins in patients with chronic liver disease (CLD), including cirrhosis, and have transformed the impossible into not only the possible, but the commonplace [1][2][3][4]. It may have taken more than 20 years, but even the Food and Drug Administration (FDA) has changed the prescribing information labels of statins, eliminating the requirement for liver-associated enzyme monitoring in patients with normal liver-associated enzymes (LAEs) [5].…”

mentioning

confidence: 99%

See 3 more Smart Citations

Prescribing a Statin to a Cirrhotic Patient to Reduce Hepatic Decompensation and Improve Survival: Impossible You Say?

Lewis

2014

Dig Dis Sci

View full text Add to dashboard Cite

Section: Biopsy-proven Versus Clinically Diagnosed Cirrhosismentioning

confidence: 81%

Section: How To Monitor Laes In Patients With Cirrhosis Taking a Statin?mentioning

confidence: 99%

Section: Should Statins Be Routinely Prescribed To Patients With Cirrmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Prescribing a Statin to a Cirrhotic Patient to Reduce Hepatic Decompensation and Improve Survival: Impossible You Say?

Lewis

2014

Dig Dis Sci

View full text Add to dashboard Cite

“…Although serious hepatotoxicity is rare, 30 cases of liver failure associated with statin use were reported to the FDA between 1987 and 2000, the rate being about one case per million person-years of use. Thus, the occurrence of acute liver failure thought to be caused by statins is well below the background rate of idiopathic acute liver failure in the general population [132] . Evidence from four cohort studies and case reports suggest that statins cause reversible peripheral neuropathy.…”

Section: Side Effects Of Statin Chemopreventionmentioning

confidence: 99%

Role of chemoprophylaxis with either NSAIDs or statins in patients with Barrett’s esophagus

Tsibouris

Vlachou

Isaacs

2014

WJGPT

View full text Add to dashboard Cite

The incidence of esophageal adenocarcinoma, a poor prognosis neoplasia, has risen dramatically in recent decades. Barrett's esophagus represents the best-known risk factor for esophageal adenocarcinoma development. Non-steroidal anti-inflammatory drugs through cyclooxygenase-2 inhibition and prostaglandin metabolism regulation could control cell proliferation, increase cell apoptosis and regulate the expression of growth and angiogenic factors. Statins can achieve equivalent effects through prenylation and subsequently control of cellular signaling cascades. At present, epidemiological studies are small and underpowered. Their data could not justify either medication as a chemo-preventive agent. Population based studies have shown a 43% reduction of the odds of developing an esophageal adenocarcinoma, leaving out or stating a 25% reduction in patients consuming non-aspirin nonsteroidal antiinflammatory drugs and a 50% reduction in those patients consuming aspirin. They have also stated a 19% reduction of esophageal cancer incidence when statins have been used. Observational studies have shown that non-steroidal anti-inflammatory drugs could reduce the adenocarcinoma incidence in patients with Barrett's esophagus by 41%, while statins could reduce the risk by 43%. The cancer preventive effect has been enhanced in those patients taking a combination of non-steroidal anti-inflammatory drugs and statins (a 74% decrease). Observational data are equivocal concerning the efficacy of non-steroidal anti-inflammatory drug subclasses. Non-steroidal anti-inflammatory drugs clearly have substantial potential for toxicity, while statins are rather safe drugs. In conclusion, both non-steroidal anti-inflammatory drugs and statins are promising chemopreventive agents and deserve further exploration with interventional studies. In the meanwhile, their use is justified only in patients with cardiovascular disease.© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.Key words: Esophageal adenocarcinoma; Barrett's esophagus; Non-steroidal anti-inflammatory drugs; Aspirin; Statins; Cancer chemoprevention Core tip: Esophageal adenocarcinoma remains a major burden upon health. Experimental studies have suggested that non-steroidal anti-inflammatory drugs and statins may have useful actions against esophageal cancer cells. This review of observational studies shows that non-steroidal anti-inflammatory drugs reduced adenocarcinoma incidence in patients with Barrett' s esophagus by 41%, while statins reduced the risk by 43%. The cancer preventive effect is enhanced in those patients taking a combination of non-steroidal anti-inflammatory drugs and statins (a 74% decrease). Non-steroidal anti-inflammatory drugs clearly have substantial potential for toxicity, while statins are rather safe drugs. Their combination offers promise for chemoprevention and further interventional studies are warranted.Tsibouris P, Vlachou E, Isaacs PET. Role of chemoprophylaxis REVIEWOnline Submissions: http://www.wjgnet.com/esps/

show abstract

Drug‐Induced Liver Disease

Lilly

2012

Hepatology: Diagnosis and Clinical Management

View full text Add to dashboard Cite

The Myth of Statin-Induced Hepatotoxicity

Cited by 71 publications

References 14 publications

Prescribing a Statin to a Cirrhotic Patient to Reduce Hepatic Decompensation and Improve Survival: Impossible You Say?

Prescribing a Statin to a Cirrhotic Patient to Reduce Hepatic Decompensation and Improve Survival: Impossible You Say?

Role of chemoprophylaxis with either NSAIDs or statins in patients with Barrett’s esophagus

Drug‐Induced Liver Disease

Contact Info

Product

Resources

About